Merck & Co., Inc. (NYSE:MRK) Shows Strong Growth and Positive Analyst Outlook

Font: Financial Modeling Prep  • Aug 12, 2026

• Merck & Co., Inc. (NYSE:MRK) received an "Outperform" rating and a $143.00 price target from Daiwa, indicating a 9.62% potential upside.
• The pharmaceutical giant reported robust Q2 2026 revenue of $16.6 billion, a 5% increase, driven by strong KEYTRUDA sales of $8.4 billion.
• Significant growth in other pipeline products like WELIREG (67% increase to $271 million) and WINREVAIR (75% increase to $588 million) highlights the company's strong drug development.

Merck & Co., Inc. (NYSE:MRK) is a global pharmaceutical company that develops and produces medicines and vaccines. With a market capitalization of approximately $322.19 billion, it is a major player in the healthcare industry. As highlighted by Barrons, Merck & Co., Inc. competes with firms like Moderna (NASDAQ: MRNA) and Summit Therapeutics (NASDAQ: SMMT) in developing new treatments for cancer and cardiac conditions.

On August 12, 2026, analyst firm Daiwa upgraded its rating for Merck & Co., Inc. to "Outperform." It also set a new price target of $143.00. At the time, the stock was trading at $130.45, which suggests a potential upside of 9.62%. The primary reason cited for this positive outlook was the company's pipeline success.

This optimistic view is shared by other analysts. According to a Zacks Investment Research report, Merck & Co., Inc. holds an average brokerage recommendation (ABR) of 1.76 on a 1-to-5 scale, where 1 means "Strong Buy." This rating comes from 29 brokerage firms, with 17 of them advising a 'Strong Buy' for the stock.

The company's recent performance supports this confidence. In its Q2 2026 earnings report, Merck & Co., Inc. announced total revenue of $16.6 billion, a 5% increase. Sales of its main cancer drug, the KEYTRUDA Family, grew 4% to $8.4 billion, showing strong demand and increased use in treating earlier-stage cancers.

Other products also show significant growth, reflecting a strong pipeline. Sales for WELIREG increased by 67% to $271 million, while WINREVAIR sales rose 75% to $588 million. This growth is driven by new international launches and strong demand in the United States for its various treatments.